|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.578 EUR | -1.97% |
|
-1.30% | -1.47% |
| 06-18 | Nordea raises target price for Lundbeck to DKK60 (57), reiterates buy rating | FW |
| 06-14 | H. Lundbeck A/S Presents Preliminary Phase II Part A Data for Asedebart in Cushing's Disease | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Pharmaceuticals Wholesale
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 94.36B | |||||
| 55.23B | |||||
| 22.56B | |||||
| 8.01B | |||||
| 7.6B |
- Stock Market
- Stocks
- HLUN B Stock
- LUNB Stock
- Charts Lundbeck
- Sector Chart
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
